Recent Updates
Recently added Catalysts
RADX Negative Sentiment Score: 40/100

Suspension from Quotation

Monday, June 24, 2024 1 min read
Key Takeaway: Radiopharm Theranostics has been suspended from quotation, raising concerns about its financial health. The company has faced scrutiny due to a lack of recent positive developments and ongoing challenges. This suspension may impact investor confidence and the company's market position.

Market Sentiment Analysis

CONCERNS & RISKS

  • Suspension from quotation indicates potential financial instability.
  • Lack of recent positive updates may raise investor concerns.

Full Press Release Details

• Announcements
• Price Sensitive
• June 24, 2024
Loading Viewer…

More Announcements & Updates

• Updates
• November 27, 2024
• Announcements
• December 22, 2023
• Announcements
• April 13, 2022
• Announcements
• March 1, 2024

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What does the suspension from quotation mean?

The suspension from quotation indicates that Radiopharm Theranostics may be facing financial difficulties.

Are there any recent updates from Radiopharm Theranostics?

Recent updates have been sparse, raising concerns among investors about the company's direction.

How might this suspension affect investors?

The suspension could lead to decreased investor confidence and potential financial losses.

What is the status of Radiopharm's clinical studies?

Radiopharm has ongoing clinical studies, but recent positive updates are lacking.

Tags: RADX Viatris Investor Conferences Healthcare Radiopharm Theranostics quotation suspension financial stability clinical updates
Last updated: Jun 24, 2024